Completed acquisition of Whatman PLC
GE Healthcare recently announced its completion of the acquisition of Whatman, which is a global supplier of filtration technologies and products.
GE Healthcare recently announced its completion of the acquisition of Whatman, which is a global supplier of filtration technologies and products.Expanding GE Healthcare's life science research and biopharmaceutical manufacturing contribution, the acquisition enhances a key area of growth for the company. A provider of cellular and protein science research technologies, as well as tools used in biopharmaceuticals' manufacture - products such as vaccines, cell therapies and antibodies - GE Healthcare will secure substantial customer benefits through the addition of Whatman's innovative filters and membranes for laboratory research, life sciences and medical technology applications.GE Healthcare's president and CEO of life sciences business commented: "Whatman's expertise and reputation on filtration technologies and sample preparation is a great fit for our life sciences business. We believe that combining the skills of the two companies will enable GE Healthcare to create strong added value for customers in biomedical and drug discovery research."
RAFA 2024 Highlights: Contemporary Food Contamination Analysis Using Chromatography
November 18th 2024A series of lectures focusing on emerging analytical techniques used to analyse food contamination took place on Wednesday 6 November 2024 at RAFA 2024 in Prague, Czech Republic. The session included new approaches for analysing per- and polyfluoroalkyl substances (PFAS), polychlorinated alkanes (PCAS), Mineral Oil Hydrocarbons (MOH), and short- and medium-chain chlorinated paraffins (SCCPs and MCCPs).
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
